Dr. Carlos Ramos, MD
Claim this profileHouston Methodist Hospital
Area of expertise
Non-Hodgkin's Lymphoma
Carlos Ramos, MD has run 7 trials for Non-Hodgkin's Lymphoma. Some of their research focus areas include:
Acute Lymphoblastic Leukemia
Carlos Ramos, MD has run 5 trials for Acute Lymphoblastic Leukemia. Some of their research focus areas include:
Affiliated Hospitals
Houston Methodist Hospital
Texas Children's Hospital
Clinical Trials Carlos Ramos, MD is currently running
CAR T Cell Therapy
for Lymphoma
The subject has a type of lymph gland cancer called Lymphoma. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected with germs. Both antibodies and T cells have been used to treat patients with cancers; they both have shown promise, but have not been strong enough to cure most patients. Investigators hope that both will work better together. Investigators have found from previous research that they can put a new gene into T cells that will make them recognize cancer cells and kill them. They now want to test whether these genetically modified T cells given after chemotherapy will be more effective at killing cancer cells. The gene that will be put into the T cells makes an antibody called anti-CD30. This antibody sticks to lymphoma cells because of a substance on the outside of the cells called CD30. Anti-CD30 antibodies have been used to treat people with lymphoma, but have not been strong enough to cure most patients. For this study, the anti-CD30 antibody has been changed so that instead of floating free in the blood it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD30 chimeric receptor-activated T cells (CD30.CAR T cells) seem to kill some of the tumor, but they don't last very long and so their chances of fighting the cancer are unknown. Several studies suggest that the infused T cells need room to be able to multiply and grow to accomplish their functions, and that this may not happen if there are too many other T cells in circulation. Because of that, doctors may use chemotherapy drugs to decrease the level of circulating T cells prior to the CD30.CAR T cells infusion. This is called "lymphodepletion" CD30.CAR T cells have previously been studied in lymphoma patients.
Recruiting
1 award
Phase 1
CAR T-Cell Therapy
for Leukemia and Lymphoma
Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "lymphoma" or "leukemia"). The lymphoma or leukemia has come back or has not gone away after treatment. The body has different ways of fighting infection and disease. No one way seems perfect for fighting cancers. This research study combines two different ways of fighting disease, antibodies and T cells, hoping that they will work together. Both antibodies and T cells have been used to treat patients with cancer. They have shown promise, but have not been strong enough to cure most patients. T cells can kill tumor cells but normally there are not enough of them to kill all the tumor cells. Some researchers have taken T cells from a person's blood, grown more of them in the laboratory and then given them back to the person. The antibody used in this study is called anti-CD19. It first came from mice that have developed immunity to human lymphoma. This antibody sticks to lymphoma cells because of a substance on the outside of these cells called CD19. CD19 antibodies have been used to treat people with lymphoma and leukemia. For this study, anti-CD19 has been changed so that instead of floating free in the blood it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. In the laboratory, the investigators found that T cells work better if they also add proteins that stimulate T cells, such as one called CD28. Adding the CD28 makes the cells last longer in the body but not long enough for them to be able to kill the lymphoma cells. The investigators believe that if they add an extra stimulating protein, called CD137, the cells will have a better chance of killing the lymphoma cells. The investigators are going to see if this is true by putting the CD19 chimeric receptor with CD28 alone into half of the cells and the CD19 chimeric receptor with CD28 and CD137 into the other half of the cells. These CD19 chimeric receptor T cells with CD28 and with or without CD137 are investigational products not approved by the FDA. The purpose of this study is to find the biggest dose of chimeric T cells that is safe, to see how long the T cell with each sort of chimeric receptor lasts, to learn what the side effects are and to see whether this therapy might help people with lymphoma or leukemia.
Recruiting
1 award
Phase 1
More about Carlos Ramos, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Carlos Ramos, MD has experience with
- Fludarabine
- Cyclophosphamide
- Nivolumab
- CD19.CAR-aNKT Cells
- CD19.CAR-CD28Z T Cells
- CD19CAR/virus Specific T Cells
Breakdown of trials Carlos Ramos, MD has run
Non-Hodgkin's Lymphoma
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Cutaneous T-Cell Non-Hodgkin Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Carlos Ramos, MD specialize in?
Carlos Ramos, MD focuses on Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia. In particular, much of their work with Non-Hodgkin's Lymphoma has involved CD19 positive patients, or patients who are CD30 positive.
Is Carlos Ramos, MD currently recruiting for clinical trials?
Yes, Carlos Ramos, MD is currently recruiting for 2 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Carlos Ramos, MD has studied deeply?
Yes, Carlos Ramos, MD has studied treatments such as Fludarabine, Cyclophosphamide, Nivolumab.
What is the best way to schedule an appointment with Carlos Ramos, MD?
Apply for one of the trials that Carlos Ramos, MD is conducting.
What is the office address of Carlos Ramos, MD?
The office of Carlos Ramos, MD is located at: Houston Methodist Hospital, Houston, Texas 77030 United States. This is the address for their practice at the Houston Methodist Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.